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COMPARABLE LONG-TERM LEUKEMIA-FREE SURVIVAL AFTERMATCHED
SIBLING AND UNRELATED DONOR TRANSPLANTATION FOR CHILDREN
WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN SECOND COMPLETE RE-
MISSION
Thiel, E.L.1, Zhang, M.-J.1, Davies, S.M.2, Kurtzberg, J.3, Logan, B.1,
Ayas, M.4, MacMillian, M.L.5, Tiedemann, K.6, Eapen, M.1 1Medical
College of Wisconsin, Milwaukee, WI; 2Cincinnati Children’s Hospital,
OH; 3Duke University Hospital, Durham, NC; 4King Faisal Specialist
Hospital & Research Center, Riyadh, Saudi Arabia; 5University of Min-
nesota Medical School, Minneapolis, MN; 6Royal Children’s Hospital,
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The best treatment for children with acute lymphoblastic leuke-
mia (ALL) in second complete remission (CR) after an early bone
marrow (BM) relapse (#36 months from diagnosis) is an HLA-
matched sibling transplant. However, only a third of children who
would benefit from this treatment have a matched sibling. Trans-
plantation using a suitably matched unrelated donor is controversial
given the risks of treatment-related mortality (TRM) is higher and
may have an adverse effect on leukemia-free survival (LFS). To ad-
dress this question, we compared transplant-outcomes in 92 recipi-
ents of HLA-matched sibling BM transplantations and 229
recipients of unrelated donor transplantations (n5 156, BM graft
and n5 73, cord blood [CB]). Patients were aged 1-15 years, had
early relapse and were in second CR at transplantation. Transplants
occurred from 1997 to 2005, and the median follow up of surviving
patients was 5 years. CB recipients were younger (median 6 years)
compared to unrelated BM (7 years) and matched sibling BM recip-
ients (8 years). All patients received total body irradiation containing
conditioning regimens and calcinuerin inhibitor containing graft-
versus-host disease (GVHD) prophylaxis. Forty-nine percent of un-
related donor BM recipients were matched at HLA-A, -B, -C, and
-DRB1, and 14% of CB matched at HLA-A, -B, and -DRB1, the
standard for this graft. We first examined TRM, leukemia relapse
and LFS after unrelated donor BM and CB transplantation and
found no differences. Therefore, for all subsequent analyses, all un-
related donor transplant recipients were grouped together. In multi-
variate analysis, we observed no differences in risks of
relapse(RR5 0.9, p5 0.092) or treatment failure [death or relapse,
inverse of LFS] (RR5 1.2, p5 0.291) after HLA-matched sibling
and unrelated donor transplant. Compared to HLA-matched sibling
transplant, grade 2-4 acute GVHD (RR 2.8, p\0.001), chronic
GVHD (RR 4.2, p\0.001) and TRM (RR5 1.9, p5 0.045), were
higher after unrelated donor transplants. The table below shows
the probabilities (95% confidence interval [CI]) of acute GVHD at
day-100, chronic GVHD, TRM, relapse and LFS at 3-years.
When transplantation is the optimal treatment option, transplanta-
tion of BM from a suitably matched unrelated donor or CB unit
with an adequate cell dose is an acceptable alternative for children
without an HLA-matched sibling.
Transplant TypeOutcome HLA-matched sibling Unrelated donorAcute GVHD* 22% (95% CI 15-31) 51% (95% CI 45-57)
Chronic GVHD* 10% (95% CI 5-17) 30 % (95% CI 25-36)
TRM* 13% (95% CI 7-20) 26% (95% CI 20-31)
Relapse 37% (95% CI 27-47) 31% (95% CI 25-37)
LFS 50% (95% CI 40-60) 43% (95% CI 37-49)* indicates statistical significance.295
THE COSTS AND COST-EFFECTIVENESS OF ALLOGENEIC PERIPHERAL
BLOOD STEM CELL TRANSPLANTATION VERSUS BONE MARROW TRANS-
PLANTATION IN PEDIATRIC PATIENTS WITH ACUTE LEUKEMIA
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In a retrospective study, we evaluated the cost and cost-effective-
ness of allogeneic peripheral blood stem cell transplantation
(PBSCT) (n5 30) compared with bone marrow transplantation
(BMT) (n5 110) in children with acute leukemia at 1 year of follow
up. Treatment success was defined as disease free survival at one year
post transplant. The inpatient days (42.9 d for PBSCT; 36.8 d for
BMT) and costs from day of admission to transplantation to day of
discharge ($282,577 for PBSCT; $208,987 for BMT) were not sig-
nificantly different between these two groups during the initial hos-
pitalization for transplantation. From the initial hospitalization to
100 days post transplant, the PBSCT group cost was $147,906 com-
pared to $103,428 for the BMTgroup (P5NS). From 100 days post
transplant to 1 year, PBSCT cost was $106,683 compared to
$124,578 for BMT (P5NS). For standard risk disease patients the
treatment success rate was 57.1% for PBSCT patients and 80.3%
for recipients of BMT (P5NS). The average total cost per treat-
ment success at 1 year in the standard risk disease group was
$512,294 for the PBSCT group and $352,885 for the BMT group
(P5NS). For patients with high risk disease, the treatment success
rate was 18.8% for PBSCT patients and 23.5% for BMT (P5NS).
The cumulative average cost for patients in the BMT group was
$457,078 compared to $377,316 for PBSCT (P5NS). Point esti-
mates of the incremental cost-effectiveness ratio (ICER) indicate
that allogeneic transplantation of bone marrow grafts is dominant
over PBSCT for its lower costs and higher effectiveness in patients
with standard risk disease (ICER5 -$687,108; 95% CI5 $2.4 mil-
lion to dominated). For patients with high risk disease, BMT was
more effective and more costly and the ICER was $1.69 million
(95% CI5 $29.7 million to dominated) per additional treatment
success. The comparative economic evaluation provides support
for BMT for standard risk patients, but the large degree of uncer-
tainty precludes definite support for either treatment option in pa-
tients with high risk disease.296
ALDEHYDE DEHYDROGENASE CELL DOSING PREDICTS THE DOMINAT-
ING CORD IN DOUBLE CORD BLOOD TRANSPLANTATION
Page, K.M.1, Gentry, T.2, Shoulars, K.1, Horwitz, M.E.3,
Herrmann, N.2, Meadows, N.2, Philipps, B.2, Balber, A.2,
Kurtzberg, J.1 1Duke University Medical Center, Durham, NC; 2Alda-
gen, Inc, Durham, NC; 3Duke University Medical Center, Durham, NC
Use of two cord blood units (CBU) for transplantation of a single
patient has increased access to cord blood transplantation (CBT) for
patients previously limited by the cell dose from a single CBU.With
two CBUs, cell dose can be increased above critical thresholds but,
typically, one CBU confers durable engraftment. To date, it has
not been possible to predict which CBU will engraft. We are inter-
ested in hematopoietic stem cells expressing high levels of aldehyde
dehydrogenase [ALDHbr], an intracellular enzyme enumerated by
rapid flow cytometric assay. We have shown that ALDHbr dose cor-
relates with CBU potency. We hypothesize that the CBU delivering
the highest ALDHbr dose establishes durable engraftment after dou-
ble CBT (dCBT).
Methods: From 9/07-3/09, 27 consecutive adult and pediatric pa-
tients underwent dCBT for malignancies. Most (n5 24) received
myeloablative conditioning. We prospectively measured the
ALDHbr dose from both CBUs at time of thaw (Aldecount , Alda-
gen, Inc). Patient and graft characteristics were correlated with out-
comes. Engraftment was defined as the first of 3 days with anS267
S268 Poster Session IIabsolute neutrophil count of$500 cells/mm3 with.75%donor chi-
merism (RFLP confirmed). The dominating CBU was defined by
chimerism.75%. ALDHbr dosing was defined as high if the thawed
CBU delivered .47,000 ALDHbr cells/kg which was identified as
predictive of engraftment in single CBT in prior studies.
Results: The median patient age was 28.8 years (range, 3.7-64.8
years) and weight of 68.70 kg (range, 15.2-111.8 kg), 17 male, 13
CMV+. The median TNC per CBU was 2.2107/kg (range, 1.2-
10.3107/kg) with the median combined TNC of 3.9107/kg
(range, 2.7-18.0107/kg). 5 patients received two high ALDHbr
units, 10 patients received one high and one low ALDHbr unit,
and 12 received two low ALDHbr units. 23 patients were evaluable
for engraftment. 10 of 12 patients receiving $1 high ALDHbr
CBUs engrafted. The other 2 patients died of infection without en-
graftment (days 29 and 34 post-CBT). Conversely, 4 of 9 patients re-
ceiving low ALDHbr CBUs failed to engraft. In the high/low group,
only the high ALDHbr CBUs engrafted. The sensitivity and specific-
ity for ALDHbr dose is 0.71 and 0.67, respectively. The positive and
negative predictive values are 0.86 and 0.44, respectively. Other graft
parameters did not predict the dominating CBU.
Conclusion: Post-thaw ALDHbr dosing has a high positive predic-
tive value for predicting engraftment in dCBT. Further studies are
planned.
Table 1. ALDHbr Content of Units and Engraftment Status
ALDHbr Content of UnitsLow/Low High/Low High/HighTotal Patients 12 10 5
Evaluable Patients 9 9 5
Engrafted 5 7 [all with high unit] 5
Non-Engrafted 4 2297
COMPARATIVE EFFECTIVENESS ANALYSIS OF CD34 + SELECTED, T-CELL
DEPLETED (TCD) HLA-MATCHED SIBLING GRAFTS ON ALLOGENEIC HE-
MATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS WITH ACUTE
MYELOID LEUKEMIA (AML) IN COMPLETE REMISSION
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Wingard, J.R.5, Lazarus, H.M.6, Appelbaum, F.R.7, Keever-
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Milwaukee, WI; 2Ohio State University Medical Center, Columbus, OH;
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tute, Boston, MA; 5University of Florida, Shands Cancer Center, Gaines-
ville, FL; 6Case Western Reserve University, School of Medicine,
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WA; 8Memorial Sloan-Kettering Cancer Center, New York, NY; 9On be-
half of the Blood and Marrow Transplant Clinical Trials Network
Numerous single institution studies have demonstrated that TCD
significantly reduces the incidence of graft-versus-host-disease
(GVHD). However, concerns about leukemia relapse, graft rejec-
tion, and variability in technique have limited the widespread appli-
cation of this approach. Promising results of TCD in patients with
AML prompted the Blood and Marrow Transplant Clinical Trials
Network (BMT CTN) to study a single uniform technique of CD
34+ selection using the Miltenyi CliniMacs device in a Phase II clin-
ical trial (BMT CTN 0303) of adult AML patients in first or second
complete remission (CR1/CR2) receiving peripheral blood stem cell
(PBSC), HLA-matched sibling donor transplants. We compared
outcomes of the 44 patients transplanted on the BMT CTN 0303
trial to a contemporary cohort of 102 patients with AML enrolled
on the BMT CTN 0101 – Phase III clinical trial of anti-fungal pro-
phylaxis after myeloablative HCTwith pharmacologic immune sup-
pression post-transplant (IST). This analysis compared TCD (BMT
CTN #0303) versus IST (BMTCTN 0101) with respect to the end-
points of: neutrophil engraftment (ENG), rates of acute and chronic
GVHD, transplant-related mortality (TRM), relapse, disease-free
survival (DFS), and overall survival (OS). Groups were similar for pa-
tient-, disease- and transplant specific characteristics except for the
proportion of patients in CR2 (TCD 7% vs. IST 27%), unfavorable
risk cytogenetics (TCD 32% vs. IST 18%), the use of mobilizedPBSC (TCD 100% vs. IST 81%) and graft composition (TCD #1
x105 CD3+ cells/kg). The results revealed lower rates of grades II-
IV acute (p5 0.046) and chronic GVHD (p5 0.01) in the TCD
group with no difference in ENG, leukemia relapse and TRM.
DFS and OS were similar between the two groups in the univariate
setting and also after adjustment for potential prognostic factors us-
ing a Cox proportional hazards model. Reduction of GVHD rates
without an increase in relapse rates and no requirement for post-
transplant immunosuppression are distinct advantages of this
method of TCD. These results support the extension of this ap-
proach to the unrelated donor setting and additional larger, prospec-
tive studies to definitively address the role of rigorous TCD inHCT.
TCD vs ISTOutcomes
TCD % (95% IST % (95%Outcome
Confidence Interval)
N5 44
Confidence
Interval) N5 102DFS at 6 mo 81 (66-90) 75 (68-87)
Relapse at 12 mo 19 (6-32) 19 (11-26)
TRM at 12 mo 19 (6-31) 22 (14-30)
ENG at 28 d 100 (86-100) 90 (79-100)
Acute GVHD II-IV at 100 d 20 (9-32) 37 (28-47)
Acute GVHD III-IV at 100 d 5 (0-11) 10 (4-16)
Chronic GVHD at 12 mo 19 (7-32) 47 (35-58)
Overall Survival at 12 mo 74 (57-85) 69 (59-77)298
PRECLINICAL EVALUATION OF HUMAN NOR-EPINEPHRINE TRANS-
PORTER (HNET)/MIBG REPORTER SYSTEM FOR IMAGING ADOPTIVELY
TRANSFERRED EBV-SPECIFIC CYTOTOXIC T-LYMPHOCITES
Doubrovin, M., Doubrovina, E., Moroz, M., Pankov, D., Wang, X.,
Olszewska,M., Riviere, I., O’Reilly, R., Larson, S., Blasberg, R.Memorial
Sloan-Kettering Cancer Center, New York, NY
Background:Wepreviously demonstrated hNET/MIBG to be a re-
porter gene system feasible for non-invasive quantitative monitoring
of cytotoxic T-cells (CTLs) in vivo. In this preclinical study, we test
whether the hNET reporter gene construct, under conditions simu-
lating adoptive immune cell therapy in patients, is potentially appli-
cable imaging paradigm.
Methods:The hNET reporter gene was cloned into a clinical grade
SFG pseudotypedMoMLV retroviral backbone, packaged in PG-13
retroviral producer cell line andwas used to transfect EBV-specificT
cells. Following the future clinical protocol, EBV-specific T cells
were pre-generated from a normal donor by stimulation with autol-
ogous EBV-transformed B-cells, as we previously described. Based
on expression of LNGFR, a selection gene in the same retroviral cas-
sette, reporter-gene expressing cells (CTL-NIN) were selected by
FACS sorting, characterized for cytotoxicity and frozen for long-
term storage. Initially, 123I-MIBG uptake was evaluated in the
CTL-NIN retrieved from liquid nitrogen storage according to
GMP requirements. In the preclinical study, upon thawing, prior
to adoptive transfer, CTLs were preincubated with 100 microCi/
ml (3.73 MBq/ml) of 124I-MIBG for 2 hours and injected into the
EBV-BLCL xenograft tumor model bearing NOD-SCID mice. As-
sessment MIBG radioactivity in CTL-NIN prior to injection and
MicroPET imaging of the injected radiolabeled cells in a phantom
and in the animals, with post-mortem ex-vivo radioactivity measure-
ments were performed.
Results: CTL-NINs were produced according to GMP procedures
appeared to have .90% reporter gene expression post-sorting with
improved specificity to EBV-BLCL targets (35% with 10:1 E:T ra-
tio). Storage and thawing decreased their cytotoxicity (25%) and
123I-MIBG uptake (217 ml/g, compared to 330 ml/g pre-freezing).
124I-MIBG labeling of CTL-NIN T cells ex-vivo was sufficient for
in vivo imaging. In vivo microPET imaging confirmed our ability
to detect 105 124I-MIBG ex vivo prelabeled CTL-NIN distributed
in a 1 cm3 tumor volume.
Conclusions: 1) hNET transduced CTLs produced and prepared
for adoptive immune cell transfer according to a clinical protocol
